The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….

  • Spot On CML Grows in the Philippines

    Spot On CML Grows in the Philippines

    Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

  • The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….